Omnicell (NASDAQ:OMCL) Releases Q2 2026 Earnings Guidance

Omnicell (NASDAQ:OMCL) updated its second quarter 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 0.400-48.000 for the period, compared to the consensus earnings per share estimate of 0.370. The company issued revenue guidance of $307.0 million-$313.0 million, compared to the consensus revenue estimate of $304.3 million. Omnicell also updated its FY 2026 guidance to 1.800-2.000 EPS.

Omnicell Price Performance

OMCL traded up $0.48 during trading on Thursday, hitting $43.58. 154,768 shares of the stock traded hands, compared to its average volume of 628,355. The business has a 50 day moving average price of $37.11 and a 200 day moving average price of $39.43. The company has a market cap of $1.98 billion, a price-to-earnings ratio of 1,086.60, a PEG ratio of 1.35 and a beta of 0.85. Omnicell has a twelve month low of $22.66 and a twelve month high of $55.00. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.43 and a quick ratio of 1.22.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. The firm had revenue of $309.88 million for the quarter, compared to analysts’ expectations of $304.01 million. Omnicell had a net margin of 0.17% and a return on equity of 3.00%. The company’s revenue was up 14.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.26 earnings per share. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. Equities research analysts forecast that Omnicell will post 0.92 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on OMCL. Zacks Research raised shares of Omnicell from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Wall Street Zen cut shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. KeyCorp lifted their target price on Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a report on Tuesday. Bank of America raised Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 target price on the stock in a report on Wednesday, February 4th. Finally, Piper Sandler reissued an “overweight” rating and issued a $49.00 price target (down from $63.00) on shares of Omnicell in a research note on Friday, February 6th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $59.86.

Insiders Place Their Bets

In other Omnicell news, EVP Corey J. Manley sold 7,405 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $34.69, for a total transaction of $256,879.45. Following the completion of the sale, the executive vice president directly owned 96,717 shares in the company, valued at approximately $3,355,112.73. This trade represents a 7.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 2.92% of the company’s stock.

Institutional Trading of Omnicell

Institutional investors and hedge funds have recently made changes to their positions in the stock. Raymond James Financial Inc. purchased a new stake in shares of Omnicell during the 2nd quarter valued at $26,000. Kemnay Advisory Services Inc. purchased a new stake in shares of Omnicell during the 4th quarter valued at $58,000. Parkside Financial Bank & Trust raised its position in shares of Omnicell by 1,708.1% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock valued at $61,000 after buying an additional 1,264 shares in the last quarter. Van ECK Associates Corp raised its position in shares of Omnicell by 75.1% during the 4th quarter. Van ECK Associates Corp now owns 2,294 shares of the company’s stock valued at $104,000 after buying an additional 984 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its position in shares of Omnicell by 385.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company’s stock valued at $146,000 after buying an additional 3,932 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.